key: cord-0747529-6q0qvxy7
authors: Onteddu, Sanjeeva Reddy; Nalleballe, Krishna; Siddamreddy, Suman; Jasti, Madhu; Kovvuru, Sukanthi; Dandu, Vasuki; Roy, Bhaskar
title: COVID-19 in patients with neurological disorders.
date: 2020-08-25
journal: Brain Behav Immun Health
DOI: 10.1016/j.bbih.2020.100131
sha: e0e6e0d6b23fb7e215251cce2461c38fc452fbd5
doc_id: 747529
cord_uid: 6q0qvxy7

nan

De-identified data on COVID-19 in patients with neurological disorder (stroke, epilepsy, movement disorders, neuromuscular disorders, multiple sclerosis (MS), neurodegenerative disorders (dementia), headaches, and sleep disorders) were extracted from TriNetX (www.trinetx.com) "COVID-19 Research Network" on July 4 th 2020 using ICD-10 codes (Appendix 1). TriNetX is a large global health collaborative clinical research platform collecting real-time electronic medical records data related to COVID-19 from a network of healthcare organizations, which is also being used by the J o u r n a l P r e -p r o o f A matched control cohort, without a known neurological disorder, who were diagnosed with COVID-19 after January 20 th , 2020, was used for comparisons. One-to-one propensity score matching was done for baseline characteristics and other comorbid conditions. The University of Arkansas Institutional Review Board (IRB) deemed this study to be 'not human subject research' (de-identified data) and gave an exempt status (appendix 1).

16,301/6,709,355 (0.24%) patients with neurological disorders developed COVID-19 (appendix 2). After 1:1 propensity matching, 13,166 patients were included each in the study and the control cohort. Patients with pre-existing neurological disorders who developed COVID-19 were more likely to be hospitalized (Odds ratio (OR) 1.28, CI 1.19-1.39), admitted to ICU (OR 1.29, CI 1.14-1.96), get intubated (OR 1.67, CI 1.43-1.96), and had higher mortality (OR 1.15, CI 1.03-1.28) ( Table 1) .

Among the subgroups, patients with previous strokes had higher ICU admission rate, patients with neuromuscular and sleep disorders had higher risk of intubation, and patients with neurodegenerative disorders (dementia) had higher risk of mortality (Table 1) . Clinical outcomes of COVID-19 in patients with headaches, multiple sclerosis, and movement disorders were similar to matching controls.

Clinical outcome of COVID-19 varied between different neurological disorders. Patients with neuromuscular disorders can have respiratory symptoms, and about 45% of patients with sleep disorders have obstructive sleep apnea, and they were more likely to be intubated, which is consistent with previous reports. 4 Center for Disease Control and Prevention (CDC) suggested that dementia is possibly a risk factor for COVID-19, and we noted higher hospitalization and mortality from COVID-19 in patients with dementia/neurodegenerative disorders. 1 Living in nursing homes, inability to properly adhere to healthcare policies, and advanced directives with do not resuscitate order may have led to increased death in this cohort. 5 In this study, we could not assess the disease severity of COVID-19, and results are based on reported data. Despite limitations, this study showed that patients with some neurological conditions, particularly dementia, are possibly more vulnerable to COVID-

J o u r n a l P r e -p r o o f 

Spectrum of neuropsychiatric manifestations in COVID-19

Is sleep apnoea a risk factor for covid-19? findings from a retrospective cohort study

Dementia care during COVID-19. The Lancet

For the Odds ratios, 95% confidence intervals are shown within parenthesis, SD-Standard Deviation

[Total number of patients in each type of neurological disorders are shown within parenthesis. Total number patients with COVID-19 in individual types of neurological disorders, based on this table, is greater than 16,301 (the total number of patients with neurological disorder who developed COVID-19), as some patient had more than one neurological disorder. However, propensity matching was done for each group separately.